This Article Full Text Full Text (PDF) All Versions of this Article: 38/3/1110    most recent 01.STR.0000258216.83927.6av1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ovbiagele, B. Articles by Saver, J. L. Search for Related Content PubMed PubMed Citation Articles by Ovbiagele, B. Articles by Saver, J. L. Related Collections Secondary prevention Cerebrovascular disease/stroke Risk Factors Other Stroke Treatment - Medical Transient Ischemic Attacks Lipid and lipoprotein metabolism

(Stroke. 2007;38:1110.)
© 2007 American Heart Association, Inc.

Emerging Therapies

Intensive Statin Therapy After Stroke or Transient Ischemic Attack

A Sparcling Success?

From the Stroke Center and Department of Neurology, University of California Los Angeles (UCLA) School of Medicine, Calif.

Correspondence to Bruce Ovbiagele, MD, Stroke Center and Department of Neurology, University of California at Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095. E-mail Ovibes@mednet.ucla.edu

Key Words: prevention • statins • stroke • TIA

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Anyone aware of the conflicting data regarding the importance of circulating cholesterol in stroke will welcome the results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.¹ Unlike with coronary heart disease, epidemiological studies often failed to demonstrate an association between elevated cholesterol levels and stroke incidence.² However, many studies did not take into account the distinct underlying pathophysiological mechanisms of stroke and instead examined conflated end points such as a combination of ischemic and hemorrhagic stroke, or total ischemic stroke without subtyping, and others did not evaluate cholesterol subfractions. In contrast, epidemiological studies that carefully distinguished ischemic and hemorrhagic strokes generally found both a modest association of elevated cholesterol with increased risk of ischemic events and of low cholesterol with an increased risk of intracerebral hemorrhage.³

HMG-CoA reductase inhibitors or "statins," which inhibit the synthesis of cholesterol that contributes to atheroma development and progression, have been shown to reduce the risk of first stroke in patients with established coronary heart disease, diabetes, or multiple cardiovascular risk factors.⁴ Indeed, as our cardiology colleagues kept finding the benefit of lower and lower cholesterol targets for reducing the risk of coronary heart disease events,⁵ the jury remained out as to what role, if any, that statins played in stroke patients without established coronary heart disease.

Subset analyses of prior clinical trials had suggested, but not definitely proved, a benefit of statin therapy in patients with prior strokes. A retrospective subset analysis of 3280 subjects with a remote (mean 4.3 . . . [Full Text of this Article]

This article has been cited by other articles:

				A. Arboix Potential Impact of Sulfonylureas in the Outcome of Type 2 Diabetic Patients With Ischemic Stroke Stroke, September 1, 2007; 38(9): 2413 - 2414. [Full Text] [PDF]